NasdaqGM:AUPHBiotechs
Aurinia Pharmaceuticals (AUPH) Stock Looks Cheap But Earnings Quality Clouds View
The market clipped Aurinia Pharmaceuticals by about 2% today, which might suggest investors saw something worrying in the print. The headline numbers tell a different story. Q2 total revenue landed at US$83.22m and basic earnings per share came in at US$0.29, both sitting comfortably within a profitable run that now stretches across several quarters. The real swing factor is Aurinia’s very large trailing 12 month earnings, heavily influenced by non cash items. This leaves the stock trading on...